Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

about

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

Item

http://www.wikidata.org/entity/Q47175955

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@en

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@nl

type

Item

label

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@en

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@nl

prefLabel

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@en

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@nl

P1476

Prognostic Value of Tumor Volu ...... nts with Incomplete Resection.

@en

P2093

Benedikt Wiestler

http://www.w3.org/2001/XMLSchema#string

Bernhard Meyer

http://www.w3.org/2001/XMLSchema#string

Claire Delbridge

http://www.w3.org/2001/XMLSchema#string

Claus Zimmer

http://www.w3.org/2001/XMLSchema#string

Florian Ringel

http://www.w3.org/2001/XMLSchema#string

Friederike Schmidt-Graf

http://www.w3.org/2001/XMLSchema#string

Jan S Kirschke

http://www.w3.org/2001/XMLSchema#string

Jens Gempt

http://www.w3.org/2001/XMLSchema#string

Julia Gerhardt

http://www.w3.org/2001/XMLSchema#string

Melanie Barz

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

P2888

s10434-017-6253-0

P304

558-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-017-6253-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092817556

http://www.w3.org/2001/XMLSchema#string

P698

29159745

http://www.w3.org/2001/XMLSchema#string